SH Pharma announced that X842 project (Octanoic acid linagliptin ester capsule) jointly developed by its wholly-owned subsidiary Sh Pharma Xin Yi and Guizhou Sheng Nuo has received the Pharmaceutical Registration Certificate issued by the National Medical Products Administration, and the application for marketing authorization of this pharmaceutical has been approved by the National Medical Products Administration.
上海医药：戊二酸利那拉生酯胶囊（X842项目）上市许可申请获得批准
sh pharma: The application for market approval of butanedioic acid linagliptin ester capsules (X842 project) has been approved.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated